Shilpa Medicare Limited, a leader in API and formulation manufacturing, has announced a major milestone in the treatment of non-alcoholic fatty liver disease (NAFLD). The company’s Investigational New Drug, Nor Ursodeoxycholic Acid (Nor UDCA), has received the green light from the Subject Expert Committee of CDSCO for treating NAFLD.
About the Author
